Avycaz® (ceftazidime/avibactam) – Expanded indications
January 26, 2024 - The FDA approved AbbVie’s Avycaz (ceftazidime/avibactam) for the pediatric population from birth (at least 31 weeks gestational age) for the treatment of complicated intraabdominal infections (cIAI); complicated urinary tract infections (cUTI), including pyelonephritis; and hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP).
Top